Advertisement

Network-Based Drug Repositioning: Approaches, Resources, and Research Directions

Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 1903)

Abstract

The wealth of knowledge and omic data available in drug research allowed the rising of several computational methods in drug discovery field yielding a novel and exciting application called drug repositioning. Several computational methods try to make a high-level integration of all the knowledge in order to discover unknown mechanisms. In this chapter we present an in-depth review of data resources and computational models for drug repositioning.

Key words

Drug repositioning Network-based drug repurposing Drug-target interaction prediction Precision medicine Interaction networks 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work has been done within the research project “Marcatori molecolari e clinico-strumentali precoci, nelle patologie metaboliche e cronico-degenerative” founded by the Department of Clinical and Experimental Medicine of University of Catania.

References

  1. 1.
    Emmert-Streib F, Tripathi S, de Matos Simoes R et al (2013) The human disease network. Sys Biomed 1:20–28CrossRefGoogle Scholar
  2. 2.
    Weng L, Zhang L, Peng Y, Huang RS (2013) Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics 14:315–324CrossRefGoogle Scholar
  3. 3.
    Hodos RA, Kidd BA, Shameer K et al (2016) In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 8:186–210CrossRefGoogle Scholar
  4. 4.
    Dovrolis N, Kolios G, Spyrou G, Maroulakou I (2017) Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases. Drug Discov Today 22:805–813CrossRefGoogle Scholar
  5. 5.
    Lotfi Shahreza M, Ghadiri N, Mousavi SR et al (2017) A review of network-based approaches to drug repositioning. Brief Bioinform. https://doi.org/10.1093/bib/bbx017 CrossRefGoogle Scholar
  6. 6.
    Alaimo S, Giugno R, Pulvirenti A (2016) Recommendation techniques for drug-target interaction prediction and drug repositioning. Methods Mol Biol 1415:441–462CrossRefGoogle Scholar
  7. 7.
    Paolini GV, Shapland RHB, van Hoorn WP et al (2006) Global mapping of pharmacological space. Nat Biotechnol 24:805–815CrossRefGoogle Scholar
  8. 8.
    Koch U, Hamacher M, Nussbaumer P (2014) Cheminformatics at the interface of medicinal chemistry and proteomics. Biochim Biophys Acta 1844:156–161CrossRefGoogle Scholar
  9. 9.
    Piro RM (2012) Network medicine: linking disorders. Hum Genet 131:1811–1820CrossRefGoogle Scholar
  10. 10.
    Bradley D (2005) Why big pharma needs to learn the three “R”s. Nat Rev Drug Discov 4:446–446CrossRefGoogle Scholar
  11. 11.
    Ghofrani HA, Osterloh IH, Grimminger F (2006) Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 5:689–702CrossRefGoogle Scholar
  12. 12.
    Weininger D (1988) SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J Chem Inf Model 28:31–36CrossRefGoogle Scholar
  13. 13.
    Heller SR, McNaught A, Pletnev I et al (2015) InChI, the IUPAC international chemical identifier. J Chem 7:23CrossRefGoogle Scholar
  14. 14.
    Xue L, Godden JW, Stahura FL, Bajorath J (2003) Design and evaluation of a molecular fingerprint involving the transformation of property descriptor values into a binary classification scheme. J Chem Inf Comput Sci 43:1151–1157CrossRefGoogle Scholar
  15. 15.
    Durant JL, Leland BA, Henry DR, Nourse JG (2002) Reoptimization of MDL keys for use in drug discovery. J Chem Inf Comput Sci 42:1273–1280CrossRefGoogle Scholar
  16. 16.
    Bolton EE, Wang Y, Thiessen PA, Bryant SH (2008) PubChem: integrated platform of small molecules and biological activities. Ann Rep Comput Chem 4:217–241CrossRefGoogle Scholar
  17. 17.
    Gaulton A, Hersey A, Nowotka M et al (2017) The ChEMBL database in 2017. Nucleic Acids Res 45:D945–D954CrossRefGoogle Scholar
  18. 18.
    Wishart DS, Feunang YD, Guo AC et al (2017) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46:D1074–D1082CrossRefGoogle Scholar
  19. 19.
    Wishart DS, Knox C, Guo AC et al (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34:D668–D672CrossRefGoogle Scholar
  20. 20.
    Keiser MJ, Roth BL, Armbruster BN et al (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25:197–206CrossRefGoogle Scholar
  21. 21.
    Yung-Chi C, Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108CrossRefGoogle Scholar
  22. 22.
    Alaimo S, Bonnici V, Cancemi D et al (2015) DT-Web: a web-based application for drug-target interaction and drug combination prediction through domain-tuned network-based inference. BMC Syst Biol 9(Suppl 3):S4CrossRefGoogle Scholar
  23. 23.
    Kuhn M, von Mering C, Campillos M et al (2008) STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res 36:D684–D688CrossRefGoogle Scholar
  24. 24.
    Liu T, Lin Y, Wen X et al (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35:D198–D201CrossRefGoogle Scholar
  25. 25.
    Lamb J (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929–1935CrossRefGoogle Scholar
  26. 26.
    Duan Q, Flynn C, Niepel M et al (2014) LINCS Canvas Browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res 42:W449–W460CrossRefGoogle Scholar
  27. 27.
    Edgar R (2002) Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207–210CrossRefGoogle Scholar
  28. 28.
    Kolesnikov N, Hastings E, Keays M et al (2015) ArrayExpress update--simplifying data submissions. Nucleic Acids Res 43:D1113–D1116CrossRefGoogle Scholar
  29. 29.
    Zheng W, Thorne N, McKew JC (2013) Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today 18:1067–1073CrossRefGoogle Scholar
  30. 30.
    Degtyarenko K, de Matos P, Ennis M et al (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res 36:D344–D350CrossRefGoogle Scholar
  31. 31.
    Nguyen D-T, Mathias S, Bologa C et al (2017) Pharos: collating protein information to shed light on the druggable genome. Nucleic Acids Res 45:D995–D1002CrossRefGoogle Scholar
  32. 32.
    Whirl-Carrillo M, McDonagh EM, Hebert JM et al (2012) Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92:414–417CrossRefGoogle Scholar
  33. 33.
    Kuhn M, Campillos M, Letunic I et al (2010) A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 6:343CrossRefGoogle Scholar
  34. 34.
    Denis A, Mergaert L, Fostier C et al (2010) A comparative study of European rare disease and orphan drug markets. Health Policy 97:173–179CrossRefGoogle Scholar
  35. 35.
    Chavali AK, Blazier AS, Tlaxca JL et al (2012) Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease. BMC Syst Biol 6:27CrossRefGoogle Scholar
  36. 36.
    Yang L, Agarwal P (2011) Systematic drug repositioning based on clinical side-effects. PLoS One 6:e28025CrossRefGoogle Scholar
  37. 37.
    Sirota M, Dudley JT, Kim J et al (2011) Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med 3:96ra77CrossRefGoogle Scholar
  38. 38.
    Dudley JT, Sirota M, Shenoy M et al (2011) Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 3:96ra76CrossRefGoogle Scholar
  39. 39.
    Chiang AP, Butte AJ (2009) Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Clin Pharmacol Ther 86:507–510CrossRefGoogle Scholar
  40. 40.
    Zhang P, Wang F, Hu J (2014) Towards drug repositioning: a unified computational framework for integrating multiple aspects of drug similarity and disease similarity. AMIA Annu Symp Proc 2014:1258–1267PubMedPubMedCentralGoogle Scholar
  41. 41.
    Emig D, Ivliev A, Pustovalova O et al (2013) Drug target prediction and repositioning using an integrated network-based approach. PLoS One 8:e60618CrossRefGoogle Scholar
  42. 42.
    Yeh S-H, Yeh H-Y, Soo V-W (2012) A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancer. J Clin Bioinform 2:1CrossRefGoogle Scholar
  43. 43.
    Chen H-R, Sherr DH, Hu Z, DeLisi C (2016) A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer. BMC Med Genomics 9:51CrossRefGoogle Scholar
  44. 44.
    Li Z, Wang R-S, Zhang X-S (2011) Two-stage flux balance analysis of metabolic networks for drug target identification. BMC Syst Biol 5(Suppl 1):S11CrossRefGoogle Scholar
  45. 45.
    Folger O, Jerby L, Frezza C et al (2011) Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol 7:501CrossRefGoogle Scholar
  46. 46.
    Yamanishi Y, Araki M, Gutteridge A et al (2008) Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 24:i232–i240CrossRefGoogle Scholar
  47. 47.
    Fakhraei S, Huang B, Raschid L, Getoor L (2014) Network-based drug-target interaction prediction with probabilistic soft logic. IEEE/ACM Trans Comput Biol Bioinform 11:775–787CrossRefGoogle Scholar
  48. 48.
    Fakhraei S, Raschid L, Getoor L (2013) Drug-target interaction prediction for drug repurposing with probabilistic similarity logic. In: Proceedings of the 12th International Workshop on Data Mining in Bioinformatics - BioKDD ’13. ACM, New York, NYGoogle Scholar
  49. 49.
    Chen H, Zhang Z (2013) A semi-supervised method for drug-target interaction prediction with consistency in networks. PLoS One 8:e62975CrossRefGoogle Scholar
  50. 50.
    van Laarhoven T, Nabuurs SB, Marchiori E (2011) Gaussian interaction profile kernels for predicting drug-target interaction. Bioinformatics 27:3036–3043CrossRefGoogle Scholar
  51. 51.
    van Laarhoven T, Marchiori E (2013) Predicting drug-target interactions for new drug compounds using a weighted nearest neighbor profile. PLoS One 8:e66952CrossRefGoogle Scholar
  52. 52.
    Xia Z, Wu L-Y, Zhou X, Wong STC (2010) Semi-supervised drug-protein interaction prediction from heterogeneous biological spaces. BMC Syst Biol 4(Suppl 2):S6CrossRefGoogle Scholar
  53. 53.
    Bleakley K, Yamanishi Y (2009) Supervised prediction of drug–target interactions using bipartite local models. Bioinformatics 25:2397–2403CrossRefGoogle Scholar
  54. 54.
    Mei J-P, Kwoh C-K, Yang P et al (2013) Drug-target interaction prediction by learning from local information and neighbors. Bioinformatics 29:238–245CrossRefGoogle Scholar
  55. 55.
    Gönen M (2012) Predicting drug-target interactions from chemical and genomic kernels using Bayesian matrix factorization. Bioinformatics 28:2304–2310CrossRefGoogle Scholar
  56. 56.
    Perlman L, Gottlieb A, Atias N et al (2011) Combining drug and gene similarity measures for drug-target elucidation. J Comput Biol 18:133–145CrossRefGoogle Scholar
  57. 57.
    Iorio F, Bosotti R, Scacheri E et al (2010) Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 107:14621–14626CrossRefGoogle Scholar
  58. 58.
    Gottlieb A, Stein GY, Ruppin E, Sharan R (2011) PREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol 7:496CrossRefGoogle Scholar
  59. 59.
    Frijters R, van Vugt M, Smeets R et al (2010) Literature mining for the discovery of hidden connections between drugs, genes and diseases. PLoS Comput Biol 6:e1000943CrossRefGoogle Scholar
  60. 60.
    Yang H-T, Ju J-H, Wong Y-T et al (2017) Literature-based discovery of new candidates for drug repurposing. Brief Bioinform 18:488–497PubMedGoogle Scholar
  61. 61.
    Wang W, Yang S, Zhang X, Li J (2014) Drug repositioning by integrating target information through a heterogeneous network model. Bioinformatics 30:2923–2930CrossRefGoogle Scholar
  62. 62.
    Zhang P, Agarwal P, Obradovic Z (2013) Computational drug repositioning by ranking and integrating multiple data sources. In: Blockeel H, Kersting K, Nijssen S, Železný F (eds) Machine learning and knowledge discovery in databases. Springer, Berlin, pp 579–594Google Scholar
  63. 63.
    Wang Y, Chen S, Deng N, Wang Y (2013) Drug repositioning by kernel-based integration of molecular structure, molecular activity, and phenotype data. PLoS One 8:e78518CrossRefGoogle Scholar
  64. 64.
    Chen X, Liu M-X, Yan G-Y (2012) Drug-target interaction prediction by random walk on the heterogeneous network. Mol Biosyst 8:1970–1978CrossRefGoogle Scholar
  65. 65.
    Berenstein AJ, Magariños MP, Chernomoretz A, Agüero F (2016) A multilayer network approach for guiding drug repositioning in neglected diseases. PLoS Negl Trop Dis 10:e0004300CrossRefGoogle Scholar
  66. 66.
    Cheng F, Liu C, Jiang J et al (2012) Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol 8:e1002503CrossRefGoogle Scholar
  67. 67.
    Alaimo S, Pulvirenti A, Giugno R, Ferro A (2013) Drug-target interaction prediction through domain-tuned network-based inference. Bioinformatics 29:2004–2008CrossRefGoogle Scholar
  68. 68.
    Alaimo S, Giugno R, Pulvirenti A (2014) ncPred: ncRNA-disease association prediction through tripartite network-based inference. Front Bioeng Biotechnol 2:71CrossRefGoogle Scholar
  69. 69.
    Zhang J, Li C, Lin Y et al (2017) Computational drug repositioning using collaborative filtering via multi-source fusion. Expt Syst Appl 84:281–289CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Clinical and Experimental MedicineUniversity of CataniaCataniaItaly

Personalised recommendations

Cite protocol

Buy options